Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211]

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin with pomalidomide and dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma after 1 or more treatments.

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

6211

Project Team

Project lead

Thomas Feist

Email enquiries

If you have any queries please email [email protected]

External Assessment Group:

Liverpool Reviews and Implementation Group, University of Liverpool

Stakeholders

Companies sponsors

GlaxoSmithKline (belantamab mafodotin)

Others

Department of Health and Social Care

 

Health Technology Wales

 

NHS England

Patient carer groups

Blood Cancer UK

 

Myeloma UK

Professional groups

Association of Cancer Physicians

 

Cancer Research UK

 

Royal College of Physicians

 

Royal College of Radiologists

 

UK Myeloma Society

Assessment group

Liverpool Reviews and Implementation Group

Associated public health groups

None

Comparator companies

Amgen (carfilzomib) (confidentiality agreement signed, participating)

 

Janssen-Cilag (bortezomib, daratumumab, teclistamab) (confidentiality agreement signed, participating)

 

Menarini Stemline UK (selinexor) (confidentiality agreement signed, participating)

 

Takeda (confidentiality agreement signed, participating)

 

AbbVie (dexamethasone) (confidentiality agreement not signed, not participating)

 

ADVANZ Pharma (dexamethasone0 (confidentiality agreement not signed, not participating)

 

AS Kalceks (dexamethasone) (confidentiality agreement not signed, not participating)

 

Aspen (dexamethasone) (confidentiality agreement not signed, not participating)

 

Aspire Pharma (bortezomib, dexamethasone) (confidentiality agreement not signed, not participating)

 

Aurobindo Pharma (bortezomib) (confidentiality agreement not signed, not participating)

 

Bausch & Lomb UK (dexamethasone) (confidentiality agreement not signed, not participating)

 

Bristol Myers Squibb Pharmaceuticals (pomalidomide) (confidentiality agreement not signed, not participating)

 

Dr. Reddy's Laboratories UK (bortezomib) (confidentiality agreement not signed, not participating)

 

Glenmark Pharmaceuticals Europe (dexamethasone) (confidentiality agreement not signed, not participating)

 

Hameln pharma (dexamethasone) (confidentiality agreement not signed, not participating)

 

Hospira UK (dexamethasone) (confidentiality agreement not signed, not participating)

 

Krka UK (dexamethasone) (confidentiality agreement not signed, not participating)

 

Martindale Pharma, an Ethypharm Group Company (dexamethasone) (confidentiality agreement not signed, not participating)

 

Medac GmbH (bortezomib) (confidentiality agreement not signed, not participating)

 

MSN Laboratories Europe (bortezomib) (confidentiality agreement not signed, not participating)

 

Mylan (bortezomib) (confidentiality agreement not signed, not participating)

 

Novartis Pharmaceuticals UK (dexamethasone) (confidentiality agreement not signed, not participating)

 

Panpharma UK (dexamethasone) (confidentiality agreement not signed, not participating)

 

ParaPharm Development (dexamethasone) (confidentiality agreement not signed, not participating)

 

Pfizer (bortezomib, elranatamab) (confidentiality agreement not signed, not participating)

 

Pharma & (panobinostat) (confidentiality agreement not signed, not participating)

 

Ranbaxy UK Limited a Sun Pharmaceutical Company (bortezomib) (confidentiality agreement not signed, not participating)

 

Rayner Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)

 

Rosemont Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)

 

Sandoz (bortezomib) (confidentiality agreement not signed, not participating)

 

Sanofi (dexamethasone, isatuximab) (confidentiality agreement not signed, not participating)

 

Santen UK (dexamethasone) (confidentiality agreement not signed, not participating)

 

Synchrony Pharma (dexamethasone) (confidentiality agreement not signed, not participating)

 

Teva UK (dexamethasone) (confidentiality agreement not signed, not participating)

 

Thame Laboratories (dexamethasone) (confidentiality agreement not signed, not participating)

 

Thea Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)

 

Thornton & Ross (bortezomib) (confidentiality agreement not signed, not participating)

 

Tillomed Laboratories (bortezomib) (confidentiality agreement not signed, not participating)

 

Wockhardt UK (dexamethasone) (confidentiality agreement not signed, not participating)

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health - NI

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

NHS Wales Joint Commissioning Committee

 

Welsh Government

Relevant research groups

Institute of Cancer Research

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual